What Дисменорм Treats: Main Uses and Benefits

The preparation is applied across therapeutic domains relevant to common menstrual cycle disorders and associated symptomatic patterns, providing supportive management for women of reproductive age. The product is commonly used to help manage symptoms associated with Premenstrual Syndrome (PMS), painful menstruation (dysmenorrhea), and general cycle inconsistencies.

This supportive therapy is relevant for addressing symptom clusters that create noticeable functional strain, including cyclical pain, breast tenderness, bloating, irritability, and mood swings. It is commonly applied in scenarios where additional symptomatic support is needed to ease the overall burden of these recurrent issues.

“This supportive action contributes to day-to-day comfort and helps maintain a sense of stability during the symptomatic phases.”

The overall therapeutic benefit is commonly associated with contributing to easing the overall symptom load. This support may assist with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Relief for Cyclical Discomfort
Main Symptom Cluster	Pain, breast tenderness, and emotional tension.
Context of Use	Supportive management of recurrent premenstrual and menstrual manifestations.
Primary Benefit	May help patients cope more steadily with symptom fluctuations.

Who Can and Cannot Use Дисменорм?

Regulatory agencies define strict population eligibility criteria for the use of Dysmenorm, primarily based on age, reproductive status, and specific medical conditions. Use of this medicine is officially permitted only for Female Adults.

---

Contraindications and Restrictions

Category	Regulatory Status
Hypersensitivity	Contraindicated in individuals allergic to the active substances or excipients.
Pediatric Use	Not recommended in children and adolescents under 18 years due to insufficient data.
Pregnancy/Lactation	Not recommended during pregnancy or lactation.
Conditional Use	Patients with a history of oestrogen-sensitive cancer or pituitary disorders must consult a physician prior to use.

---

The official eligibility profile strictly prohibits use in patients with known allergies. It limits use to adult women and advises against use during pregnancy, breastfeeding, and in those under the age of 18. Furthermore, patients with hormone-sensitive or pituitary-related medical histories are advised to seek consultation, establishing clear boundaries for conditional use as defined in regulatory documents.

Interactions with other medicines and products

This section details the official regulatory information regarding the interaction profile of Дисменорм with other medicinal products and substances. This content is strictly based on the formal statements documented in authoritative government regulatory filings for this specific product, which define its use constraints.

---

Official Interaction Profile Summary

Interaction Classification	Regulatory Statement
Interacting Substances	No specific medicinal products or product classes are explicitly listed as interacting substances in the official regulatory documentation.
Mechanistic Basis	No specific mechanistic basis for interactions, such as effects on Cytochrome P450 enzymes or drug transporters, is documented.
Procedural Requirements	No timing requirements, separation rules, or dose adjustment protocols related to drug-drug interactions are specified in the product labeling.

---

General Constraint Context

Formal studies documenting interactions between this specific product and conventional medicinal products have not been performed or are not available in the public regulatory record. Consequently, the official documentation does not contain constraints, warnings, or procedural requirements related to co-administration. The absence of documented information means the official profile does not classify interactions by severity (e.g., contraindicated, major, moderate) or provide detailed rules. This summarizes the complete official regulatory statement concerning the product's interaction structure.

The mechanism of action involves the modulation of the hypothalamic-pituitary-ovarian (H-P-O) axis. This collective effect of components leads to an alteration in the overall physiological regulation of the menstrual cycle.

Pituitary Regulation and Prolactin Modulation

The core mechanism involves a dopaminergic effect on D2 receptors in the anterior pituitary gland, resulting in the suppression and subsequent modulation of prolactin secretion back towards basal levels.

Influence on LH/FSH Ratio and Corpus Luteum

The mechanism also maintains the ratio of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. This hormonal balance influences corpus luteum function, which is a downstream physiological consequence of the initial pituitary modulation.

Anti-inflammatory Pathway Modulation

Additionally, the mechanism involves a peripheral anti-inflammatory action by modulating the cyclooxygenase (COX) and lipoxygenase (LOX) pathways. This action results in decreased inflammatory marker activity in localized tissues.

How to Use Дисменорм

The administration of this medicine is based on official instructions that define the precise method, frequency, and duration of use, consistent with its classification as a complex homeopathic medicinal product.

Official Administration Protocol

Дисменорм is officially administered via the oral route in the form of a tablet. The specific method of intake requires the tablet to be slowly dissolved in the mouth to facilitate absorption. Alternatively, for ease of use, the tablets may be dissolved in a small amount of water prior to consumption. To prevent interference with the desired effect, official instructions require the tablets to be taken half an hour before or half an hour after any meal.

Dosage Regimen and Frequency

The dosing pattern is divided into distinct phases based on the user's condition. The standard single dose for adults and adolescents over 12 years is one tablet.

Phase	Frequency (Tablets/Day)	Typical Duration Context
Initial/Acute Use	3 times per day (TID)	Used until initial improvement is achieved.
Maintenance Use	1 to 2 times per day	Used for long-term, supportive regulation.

Upon experiencing improvement in the condition, the frequency of intake is officially reduced from the initial three times daily to the maintenance regimen. The overall administration is intended for long-term use over several menstrual cycles to provide supportive regulation. Consultation with a specialist is required for treatment periods extending beyond a brief, acute use phase. If a dose is missed, the protocol is to continue with the next scheduled dose and not attempt to compensate by taking a double quantity.

Research Studies for Menstrual Cycle Disorders

Research examined conditions characterized by fluctuating or episodic manifestations, such as Premenstrual Syndrome (PMS) and associated painful menstruation (dysmenorrhea), in relation to this complex homeopathic remedy. Research explored the use of the product in populations of reproductive-age women and adolescent girls experiencing these symptoms.

The evidence base available includes several Randomized Controlled Trials (RCTs), which are a common type of controlled clinical research, along with supporting data from Systematic Reviews and Meta-analyses that focus on the primary active botanical component. These designs are used in research examining symptom intensity or variability. The clinical studies primarily measured patient-reported outcomes describing perceived discomfort. Researchers also looked at outcomes reflecting daily functioning or activity level, such as general Quality of Life (QoL).

---

Study Design and Comparison Against Placebo

Studies relevant in trials assessing short-term or episodic symptom patterns used designs that allowed for comparison. In these controlled settings, the patterns of patient-reported outcomes for the main component was observed in comparison to an inactive control substance, known as a placebo.

These studies findings describe patterns observed in the studies related to symptom evolution within the observed populations. However, evidence quality varies across studies, and some trials described patterns such as varying reported outcomes between different study populations.

---

Long-Term Evidence and Durability of Observed Patterns

Research has explored short-term symptom changes, with observation periods tracking the experience of patients across several consecutive menstrual cycles. The follow-up duration in the primary studies ranges from intermediate-term (three to six cycles) to some longer observational periods.

Long-term effects are not fully established, and there is limited information for long-term outcomes that characterize the observed patterns of use for this product beyond the initial study periods.

---

What is Still Uncertain About the Research Base

The research data related to these conditions is limited and has been assigned a moderate evidence level. This moderate rating is partly due to the methodological heterogeneity (differences in how studies are conducted) noted in systematic reviews.

Also, the majority of the available higher-certainty evidence focuses on a single active component within the remedy, meaning comparative evidence is lacking for this specific four-component combination. Key limitations include modest sample sizes in several individual studies, which may affect the generalizability of the findings. The evidence base is marked by uncertainty, and additional research is required to fully characterize the range of observed patterns.

Common questions about Дисменорм (FAQ)

Q: How quickly can I expect to notice any difference after starting Дисменорм?

Studies examining the main component of this medicine suggest that initial symptom improvement may begin to be observed after a continuous treatment period of approximately three menstrual cycles, which is about 90 days. This pattern suggests the product is consistent with a supportive, long-term approach, rather than providing immediate relief.

Q: What should I do if a side effect of Дисменорм seems unusual or bothersome?

Official regulatory guidance states that if any undesirable effects occur, especially those not listed in the patient information leaflet, a doctor or a qualified health care practitioner should be consulted. This action supports the documentation and review of any new or unusual concerns by a health professional.

Q: What are the most commonly reported side effects of Дисменорм in research?

Official documents list several possible adverse reactions, such as mild gastrointestinal issues, headache, dizziness, and skin reactions like rash. However, regulatory authorities classify the frequency for each reaction as 'not known,' meaning there is insufficient data available to reliably estimate which side effects are the most common in the patient population.

Q: Is it possible for Дисменорм to interact with supplements like vitamins or herbal teas?

Regulatory information indicates that formal studies documenting interactions between this specific product and conventional medicines have not been performed. The official product documentation does not specify any constraints related to general supplements, vitamins, or herbal teas.

Q: Are there any known issues with taking Дисменорм and driving or operating machinery?

Official regulatory documents state that no specific studies on the effect of this product on a person's ability to drive or use machines have been conducted. Officially documented undesirable effects include headache and dizziness, which patients may wish to consider.

Q: Do official documents mention the use of Дисменорм for conditions other than the primary one?

The official regulatory indication for this medicine is specifically limited to its use for supportive gynecological regulation in menstrual cycle disorders and related discomfort. No other uses are documented or officially recognized in the product's regulatory filings.

Q: What kind of research has been done on the long-term effectiveness of Дисменорм?

Research focusing on the main component has included observation periods of up to several consecutive menstrual cycles, with some studies tracking patients for up to six cycles. The current evidence base suggests that long-term effects beyond these intermediate periods are not fully established.

Q: Can I use Дисменорм during breastfeeding?

Regulatory guidance strictly advises against the use of this medicine during the period of lactation (breastfeeding). This is based on safety constraints defined in the product's official labeling.

Q: Does Дисменорм cause weight gain?

Weight gain is not listed as an officially documented adverse reaction in the regulatory documents provided for this medicine. The officially listed side effects focus on other system-organ classes, such as the gastrointestinal and nervous systems.

Q: Is common to feel stomach upset when first taking Дисменорм?

Gastrointestinal disorders, which include temporary nausea and abdominal pain, are listed as possible undesirable effects in official documentation. However, regulatory documents do not provide information on the commonality of these effects or if they are specifically more likely to occur only when an individual first starts taking the medicine.

Q: Is Дисменорм available without a prescription?

This product is typically regulated and classified by national medicines agencies as a non-prescription (over-the-counter) medicine. This means it is typically authorized for sale without a doctor’s prescription.

Q: Does taking Дисменорм affect fertility or the ability to get pregnant?

The medicine is designed to support the regulation of the menstrual cycle. While the product is contraindicated during pregnancy, official documents do not contain explicit warnings regarding long-term negative effects on the ability to become pregnant.

Q: Has Дисменорм been studied in teenagers?

Official documents state that the use of this medicine is not recommended in adolescents under 18 years of age. This restriction is due to insufficient data being available from formal regulatory-compliant studies in this specific age group.

Q: What is the risk of an allergic reaction to Дисменорм?

Severe allergic reactions, including angioedema (swelling of the face) and difficulty breathing, are documented as potential undesirable effects. As with other side effects, the official frequency of these allergic reactions is classified as not known.

Q: Does Дисменорм affect mood or cause emotional changes?

Mood alteration or changes in emotional state are not listed as officially documented adverse reactions in the regulatory documents for this medicine. The nervous system effects that are listed include headache and dizziness.

Q: Is there a maximum amount of time a person should use Дисменорм?

The product is intended for long-term supportive use. However, the official dosage instructions specify that consultation with a specialist is required for any continuous treatment periods that extend beyond a brief, initial use phase.

Q: Is there a risk of overdose with Дисменорм?

Based on official regulatory reports, no case of overdose involving this specific product has been reported.

Q: Are there different strengths or versions of the Дисменорм drug available?

Official product labeling indicates that Дисменорм is provided as a single, specific complex homeopathic formulation in the form of oral tablets.

Q: Do clinical trials on Дисменорм include women of all ages and body types?

Regulatory summaries note that the studies were conducted on populations of reproductive-age women and adolescent girls. However, official regulatory documents do not provide specific details regarding the inclusion of women of all body types in the clinical trials.

Q: Does Дисменорм contain lactose or other common allergens?

Official product information, typically found in the excipient list, confirms that the tablets contain lactose, specifically as lactose monohydrate.

Official Storage and Disposal Instructions

Storage and disposal of Dismenorm must strictly adhere to the requirements documented in official regulatory labeling.

Storage Requirement	Specification
Temperature	Does not require any special temperature storage conditions.
Protection	Must be kept out of the sight and reach of children.
Stability	Do not use after the expiry date (EXP) stated on the container.

Disposal Requirements

Unused or expired Dismenorm must be discarded in a manner that protects the environment, as stated in regulatory guidelines.

• Do not throw away the product with household waste or via wastewater (e.g., toilet or sink).
• Consult a pharmacist for proper instructions on how to dispose of medicines that are no longer needed, ensuring compliance with local pharmaceutical waste regulations.